

Media Release: Sydney. Australia. 21 September, 2021.

## **PHEBRA PLANT EXPANSION WINS NSW INDUSTRY AWARD**

Leading pharmaceutical group Phebra is proud to announce that the recent expansion of its multi-purpose sterile injectables manufacturing facility at Lane Cove West has won an award at the 2021 Australian Institute of Building (AIB) NSW Professional Excellence in Building Awards.

The two-year expansion project, managed by construction firm Johnstaff, was the winner in the Commercial Construction \$2m-\$25m category of the prestigious industry awards, which were held virtually on Friday 17 September 2021.

The works were strategically undertaken over three phases, to minimise disruptions and allow the existing facility to remain operational and to continue with the manufacture of Phebra's vital critical medicines for local and overseas markets.

Phebra Chief Executive Officer, Andre Vlok, said the expansion and reconstruction of the existing plant and its adjoining site in Orion Road, had increased the total footprint of the facility to more than 10,000 sqm.

"The team at Phebra has been very pleased with the delivery of the project and we commend Johnstaff staff and all of our contractors on their award. It's a great achievement that their work has been recognised by their NSW industry peers," Mr Vlok said today.

The extension and re-development of the plant delivers significant expansion of Phebra's packing capacity and new technology, new state of the art laboratories, additional non-sterile manufacturing and warehousing capability, additional offices, expanded critical systems and other associated infrastructure. These upgrades have resulted in Phebra being able to double their capacity to supply larger quantities of their essential critical products.

"We've bolstered our sovereign manufacturing capabilities and capacities, and continue to secure Australia's supply chain, particularly important during recent COVID outbreaks," Mr Vlok said.

Johnstaff Construction Manager, Sam Gill, said: "By far the biggest challenge faced by the project team was the requirement for construction works to occur while the remainder of Phebra's facility remained operational. Being a licensed manufacturing facility, Phebra has incredibly strict operational protocols, so it was of critical importance that their operational areas were adequately segregated from any construction works."

### **About Phebra:**

Phebra is an Australian based specialty pharmaceutical group which develops, manufactures and markets critical medicines in Australia and across the world.

***At Phebra, we create critical medicines that save and improve lives.***